Aztreonam for injection

1. Aztreonam has high antibacterial activity against most aerobic Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Oxytobacter, aerogenes, Cloacae, Proteus, Serratia, Citrobacter, Shigella and other Enterobacteriaceae, as well as influenza bacilli, gonococci, meningococci, etc. It also has good antibacterial effect against Pseudomonas aeruginosa, but has poor antibacterial effect against some Pseudomonas and Acinetobacter other than Pseudomonas aeruginosa, and has no antibacterial activity against aerobic Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as anaerobic bacteria. 2. Aztreonam inhibits the synthesis of bacterial cell walls by highly binding to penicillin-binding protein (PBP3) on the cell membrane of sensitive aerobic Gram-negative bacteria. Unlike most b-lactam antibiotics, it does not induce bacteria to produce b-lactamases and is highly stable to most b-lactamases produced by bacteria.

The main ingredient of this product is aztreonam.

It is suitable for treating various infections caused by sensitive aerobic Gram-negative bacteria, such as urinary tract infection, lower respiratory tract infection, sepsis, intra-abdominal infection, gynecological infection, postoperative wounds and burns, ulcers and other skin and soft tissue infections, etc. It is also used to treat the above-mentioned types of infections in hospital infections (such as hospital infections in immunodeficient patients).

1. Intravenous drip: Dissolve 1g of aztreonam with at least 3ml of water for injection, then dilute with appropriate infusion (0.9% sodium chloride injection, 5% or 10% glucose injection or Ringer's injection). The concentration of aztreonam should not exceed 2%, and the drip time is 20 to 60 minutes. 2. Intravenous push: Dissolve each bottle with 6 to 10ml of water for injection, and slowly inject into the vein within 3 to 5 minutes. 3. Intramuscular injection: Adults: Dissolve 1g of aztreonam with at least 3ml of water for injection or 0.9% sodium chloride injection, and inject deep into the muscle.

Adverse reactions are rare, with a systemic adverse reaction rate of about 1-1.3% or slightly lower, including gastrointestinal reactions, most commonly nausea, vomiting, diarrhea, and skin allergic reactions. Decreased white blood cell count, thrombocytopenia, Clostridium difficile diarrhea, gastrointestinal bleeding, exfoliative dermatitis, hypotension, transient electrocardiogram changes, hepatobiliary system damage, central nervous system reactions, and muscle pain are rare.

1. Patients with a history of allergy to aztreonam are prohibited from using this drug; 2. Infants and young children should use it with caution; 3. Breastfeeding women should stop breastfeeding when using this drug.

Precautions for children: The safety of infants and young children has not been established, so it should be used with caution. Precautions for pregnancy and lactation: 1. This product can enter the fetal circulation through the placenta. Although animal experiments show that it has no effect on the fetus, is non-toxic and non-teratogenic, pregnant women should still use it only when necessary. 2. It can be secreted through breast milk, and the concentration is less than 1% of the maternal blood drug concentration. When breastfeeding women use it, breastfeeding should be suspended. Precautions for the elderly: The dosage for the elderly should be reduced as appropriate according to their renal function impairment.

1. This product is combined with aminoglycosides (gentamicin, tobramycin, amikacin, etc.) to have a synergistic antibacterial effect on Pseudomonas aeruginosa, Acinetobacter, Serratia, Klebsiella, Providencia, Enterobacter, Escherichia coli, Morganella, etc. 2. This product and cefoxitin have antagonistic effects in vitro and in vivo; with naphthiocylin, cloxacillin, erythromycin, vancomycin, etc., there is no mutual interference in the efficacy.

Keep away from light and store in a sealed container.

1.0g (calculated as C13H17N5O8S2)

Hainan Quanxing Pharmaceutical Co., Ltd.

• Founded in:

  2001-10-29

• Address:

  A06-2, Bonded Area, Haikou City, Hainan Province

• Tax NO.:

  91460000730066028H

• Registered Funds:

  54.29 million yuan

• Website:

  Log in to view

• Email:

  Log in to view